| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Immunology, College of Medicine, Mayo Clinic, Rochester, MN 55905; and
Department of Molecular Pharmacology and Experimental Therapeutics, College of Medicine, Mayo Clinic, Scottsdale, AZ 85259
Lymphocyte differentiation from naive CD4+ T cells into mature Th1, Th2, Th17, or T regulatory cell (Treg) phenotypes has been considered end stage in character. In this study, we demonstrate that dendritic cells (DCs) activated with a novel immune modulator B7-DC XAb (DCXAb) can reprogram Tregs into T effector cells. Down-regulation of FoxP3 expression after either in vitro or in vivo Treg-DCXAb interaction is Ag-specific, IL-6-dependent, and results in the functional reprogramming of the mature T cell phenotype. The reprogrammed Tregs cease to express IL-10 and TGFβ, fail to suppress T cell responses, and gain the ability to produce IFN-
, IL-17, and TNF-
. The ability of IL-6+ DCXAb and the inability of IL-6–/– DCXAb vaccines to protect animals from lethal melanoma suggest that exogenously modulated DC can reprogram host Tregs. In support of this hypothesis and as a test for Ag specificity, transfer of DCXAb into RIP-OVA mice causes a break in immune tolerance, inducing diabetes. Conversely, adoptive transfer of reprogrammed Tregs but not similarly treated CD25– T cells into naive RIP-OVA mice is also sufficient to cause autoimmune diabetes. Yet, treatment of normal mice with B7-DC XAb fails to elicit generalized autoimmunity. The finding that mature Tregs can be reprogrammed into competent effector cells provides new insights into the plasticity of T cell lineage, underscores the importance of DC-T cell interaction in balancing immunity with tolerance, points to Tregs as a reservoir of autoimmune effectors, and defines a new approach for breaking tolerance to self Ags as a strategy for cancer immunotherapy.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was funded by Grants R01 CA104996 and R01 HL077296 from the National Institutes of Health (to L.R.P.).
2 Address correspondence and reprint requests to Dr. Larry R. Pease, Department of Immunology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail address: pease.larry{at}mayo.edu
3 Abbreviations used in this paper: Treg, T regulatory cell; DC, dendritic cell; RIP, rat insulin promoter; B7-DC XAb, B7-DC cross-linking Ab; DCXAb, B7-DC XAb-activated DC; DCcntrl, isotype control Ab-treated DC; WT, wild type.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  J. M. Fletcher, R. Lonergan, L. Costelloe, K. Kinsella, B. Moran, C. O'Farrelly, N. Tubridy, and K. H. G. Mills CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis J. Immunol., December 1, 2009; 183(11): 7602 - 7610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Y. Wan and R. A. Flavell How Diverse--CD4 Effector T Cells and their Functions J Mol Cell Biol, October 1, 2009; 1(1): 20 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Baban, P. R. Chandler, M. D. Sharma, J. Pihkala, P. A. Koni, D. H. Munn, and A. L. Mellor IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells J. Immunol., August 15, 2009; 183(4): 2475 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, R. Das, R. Komorowski, A. Beres, M. J. Hessner, M. Mihara, and W. R. Drobyski Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease Blood, July 23, 2009; 114(4): 891 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yuan, M. J. Ansari, F. D'Addio, J. Paez-Cortez, I. Schmitt, M. Donnarumma, O. Boenisch, X. Zhao, J. Popoola, M. R. Clarkson, et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells PNAS, June 30, 2009; 106(26): 10734 - 10739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Sharma, D.-Y. Hou, Y. Liu, P. A. Koni, R. Metz, P. Chandler, A. L. Mellor, Y. He, and D. H. Munn Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes Blood, June 11, 2009; 113(24): 6102 - 6111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Beriou, C. M. Costantino, C. W. Ashley, L. Yang, V. K. Kuchroo, C. Baecher-Allan, and D. A. Hafler IL-17-producing human peripheral regulatory T cells retain suppressive function Blood, April 30, 2009; 113(18): 4240 - 4249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yuan, J. Paez-Cortez, I. Schmitt-Knosalla, F. D'Addio, B. Mfarrej, M. Donnarumma, A. Habicht, M. R. Clarkson, J. Iacomini, L. H. Glimcher, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy J. Exp. Med., December 22, 2008; 205(13): 3133 - 3144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Radhakrishnan, L. N. Arneson, J. L. Upshaw, C. L. Howe, S. J. Felts, M. Colonna, P. J. Leibson, M. Rodriguez, and L. R. Pease TREM-2 Mediated Signaling Induces Antigen Uptake and Retention in Mature Myeloid Dendritic Cells J. Immunol., December 1, 2008; 181(11): 7863 - 7872. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
